Pyrazolyl derivatives as Syk inhibitors

US9242984B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Merck Canada Inc. · CA

Inventors

• Michelle R. Machacek · Brookline, US
• Michael D. Altman · Cambridge, US
• Eric T. Romeo · Brookline, US
• Dilrukshi Vitharana · Somerville, US
• Brandon D. Cash · Framingham, US
• Tony Siu · Brookline, US
• Hua Zhou · Acton, US
• Matthew Christopher · Brookline, US
• Solomon D. Kattar · Arlington, US
• Andrew M. Haidle · Cambridge, US
• Kaleen Konrad Childers · Medfield, US
• Matthew L. Maddess · Boston, US
• Michael H. Reutershan · Watertown, US
• Yves Ducharme · Montréal, CA
• David Joseph Guerin · Natick, US
• Kerrie Spencer · Woonsocket, US
• Christian Beaulieu · Laval, CA
• Vouy Linh Truong · ᐙᔂᓂᐲ Waswanipi, CA
• Daniel Guay · Churchill Falls, CA
• Alan B. Northrup · Reading, US
• Brandon M. Taoka · Brookline, US
• Jongwon Lim · Lexington, US
• Christian Fischer · Natick, US
• John W. Butcher · Telford, US
• Ryan D. Otte · Natick, US
• Binyuan Sun · Sharon, US
• John Michael Ellis · Needham, US

Key dates

• Filing date: Jun 18, 2013
• Grant date: Jan 26, 2016
• Expiry date: Jun 18, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.